News | January 11, 2011

EP Vendor Drops Surgical From Name

January 11, 2011 - nContact Surgical, a cardiac ablation device manufacturer, is changing its name to nContact to reflect the trend away from surgery toward percutaneous and minimally invasive procedures.

“nContact’s progressive technology and our ability to continuously provide less invasive epicardial ablation options no longer restricts our device to surgeons,” said John Funkhouser, CEO of nContact. “By removing ‘Surgical’ from our company name, we are categorically affirming our mission to transform the ablation market and change the dialogue from individual surgical or catheter approaches to interdisciplinary and EP-only approaches that may achieve greater scientific and clinical endpoints.”

The company has enabled the evolution of epicardial ablation procedures that have explored simpler access to the heart while creating complete lesions under direct visibility. It is credited with pioneering SUBTLE (SUB-thoracic TotaL Endoscopic) access to the heart, which enables a closed chest ablation procedure (without any chest incisions or ports) through a small midline abdominal incision. The primary advantage of the procedure, which utilizes the company’s Numeris Coagulation System with VisiTrax, is its unique integration of suction, perfusion, and RF-energy to create visible, continuous lesions on a beating heart.

The procedure is the first truly minimally invasive, standardized approach to access the posterior of the heart.

The company’s technology is being developed further to enable a new sub-xyphoid percutaneous approach to the atria and ventricles through a simple needle puncture.

“nContact is uniquely positioned, based on a significant scientific foundation, to demonstrate the importance of epicardial ablation to enhance the performance of existing catheter ablation tools,” said Kenneth C. Civello, M.D., chief of electrophysiology at Our Lady of the Lake Hospital in Baton Rouge, La. “The combined approach is completely synergistic with the extensive technology platform of EPs, as endocardial ablation remains important, and mapping and navigational diagnostics may predict outcomes.”

For more information: www.ncontactinc.com

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init